Vaccine hesitancy is a major issue in pediatrics and many have wondered how prevalent the issue is. A new survey offers a dispiriting answer.
Vaccine hesitancy is one of the biggest issues facing pediatrics and the 2019 measles epidemic illustrated the fallout of the movement. A survey published in Pediatrics looks at how prevalent vaccine hesitancy is among US parents.1
Researchers surveyed families with children having used the largest online panel to generate a representative US sample, which included 4445 parents. Following weighting, they calculated hesitancy using a modified 5-point Vaccine Hesitancy Scale. Parents were labeled as hesitant if they scored >3 on the scale.
Of the 4445 parents surveyed, 2176 parents completed the survey. Overall the prevalence of hesitancy was 6.1% for routine childhood immunizations and 25.8% for influenza vaccines. When asked about having concerns for serious side effects of both routine immunizations as well as influenza vaccines, 12% of the parents said they strongly agreed and 27% said that they somewhat agreed with the statement. When asked about vaccine effectiveness, 70% of parents said they strongly agreed that routine vaccines were effective, but just 26% of parents strongly agreed that influenza vaccines were also effective. Education levels lower than a bachelor’s degree along with household income <400% of the federal poverty level were found to predict hesitancy for both routine and influenza vaccines in multivariable models.
Investigators concluded that roughly 1 in 15 parents in the United States are hesitant about routine childhood vaccines and 1 in 8 parents are worried about the safety of routine childhood vaccines. Meanwhile >1 in 4 parents are hesitant about their child being given the influenza vaccine and only 1 in 4 parents believe that the vaccine is effective. The survey’s results illustrate how difficult a climb lies ahead to return vaccination rates to previous levels.
Reference:
1. Kempe A, Saville AW, Albertin C et al. Parental hesitancy about routine childhood and influenza vaccinations: a national survey. Pediatrics. 2020:145(6):e20193852. doi:10.1542/peds.2019-3852
Nirsevimab doses for 2024-2025 RSV season can be reserved with new program
February 2nd 2024Nirsevimab was approved by the FDA on July 17, 2023, ahead of the traditional RSV season, though in October, the Centers for Disease Control and Prevention (CDC) recommended it be prioritized for the highest-risk infants amid limited availability.